1-4 of 4
J. Hartlapp
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer: Results of a Three-Arm Randomized Multicenter Trial Comparing Doxorubicin, Epirubicin and Mitoxantrone Each in Combination with Cyclophosphamide

Available to Purchase
Subject Area:
Oncology
E. Heidemann, B. Steinke, J. Hartlapp, K. Schumacher, K. Possinger, S. Kunz, E. Neeser, G.v. Ingersleben, D. Hossfeld, H. Caffier, R. Souchon, R. Waldmann, E. Blümner, J. Clark
Journal: Onkologie
Onkologie (1993) 16 (5): 344–353.
https://doi.org/10.1159/000218287
Published Online: 08 May 2009
View articletitled, Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer: Results of a Three-Arm Randomized Multicenter Trial Comparing Doxorubicin, Epirubicin and Mitoxantrone Each in Combination with Cyclophosphamide
Open the PDF for Prognostic Subgroups: The Key Factor for Treatment Outcome in Metastatic Breast Cancer: Results of a Three-Arm Randomized Multicenter Trial Comparing Doxorubicin, Epirubicin and Mitoxantrone Each in Combination with Cyclophosphamide in another window
Journal Articles

Randomized Clinical Trial Comparing Mitoxantrone with Epirubicin and with Doxorubicin, each Combined with Cyclophosphamide in the First-Line Treatment of Patients with Metastatic Breast Cancer

Available to Purchase
Subject Area:
Oncology
E. Heidemann, B. Steinke, J. Hartlapp, K. Schumacher, K. Possinger, S. Kunz, E. Neeser, G.v. Ingersleben, D. Hossfeld, R. Waldmann
Journal: Onkologie
Onkologie (1990) 13 (1): 24–27.
https://doi.org/10.1159/000216714
Published Online: 27 April 2009
View articletitled, Randomized Clinical Trial Comparing Mitoxantrone with Epirubicin and with Doxorubicin, each Combined with Cyclophosphamide in the First-Line Treatment of Patients with Metastatic Breast Cancer
Open the PDF for Randomized Clinical Trial Comparing Mitoxantrone with Epirubicin and with Doxorubicin, each Combined with Cyclophosphamide in the First-Line Treatment of Patients with Metastatic Breast Cancer in another window
Journal Articles

Megestrolazetat versus Medroxyprogesteronazetat in der Behandlung metastasierender Mammakarzinome: Zwischenbericht einer multizentrischen Phase-III-Studie

Available to Purchase
Subject Area:
Oncology
H.-E. Wander, U.R. Kleeberg, E. Gärtner, J. Hartlapp, A. Scherpe, E. Bönisch, G.A. Nagel
Journal: Onkologie
Onkologie (1987) 10 (2): 104–106.
https://doi.org/10.1159/000216383
Published Online: 24 April 2009
View articletitled, Megestrolazetat versus Medroxyprogesteronazetat in der Behandlung metastasierender Mammakarzinome: Zwischenbericht einer multizentrischen Phase-III-Studie
Open the PDF for Megestrolazetat versus Medroxyprogesteronazetat in der Behandlung metastasierender Mammakarzinome: Zwischenbericht einer multizentrischen Phase-III-Studie in another window
Journal Articles

Primäre Behandlung der Haarzelleukämie mit niedrigdosiertem humanem rekombinantem Interferon-Alpha-2c (Hr-IFn Alpha 2c) im Vergleich zur Therapie nach Splenektomie: Interferon (IFn-Alpha 2c) bei HCL vor oder nach Splenektomie

Available to Purchase
Subject Area:
Oncology
H. Pralle, T. Zwingers, S. Boedewadt, K. Bross, B. Dörken, H. Gamm, A.D. Ho, R.M. Parwaresch, N. Schmitz, U. Papendick, D. Asshoff, K. Bremer, H. Euler, T. Fischer, A. Ganser, A. Goldmann, J. Hartlapp, J. Hayungs, U. Heinen, A. Heyll, J. Kraft, J. Lohmeyer, P. Meier, A. Neubauer, L. Nowicki, K. Pflüger, R. Saß, W. Schmidt, D. Schuster, K. Straif, M. Westerhausen
Journal: Onkologie
Onkologie (1987) 10 (1): 5–10.
https://doi.org/10.1159/000216357
Published Online: 24 April 2009
View articletitled, Primäre Behandlung der Haarzelleukämie mit niedrigdosiertem humanem rekombinantem Interferon-Alpha-2c (Hr-IFn Alpha 2c) im Vergleich zur Therapie nach Splenektomie: Interferon (IFn-Alpha 2c) bei HCL vor oder nach Splenektomie
Open the PDF for Primäre Behandlung der Haarzelleukämie mit niedrigdosiertem humanem rekombinantem Interferon-Alpha-2c (Hr-IFn Alpha 2c) im Vergleich zur Therapie nach Splenektomie: Interferon (IFn-Alpha 2c) bei HCL vor oder nach Splenektomie in another window